Pharma Stocks Outlook
Seen rangebound; earnings season eyed
This story was originally published at 20:30 IST on 11 July 2025
Register to read our real-time news.Informist, Friday, Jul. 11, 2025
MUMBAI – The Nifty Pharma index is likely to move within a range next week, analysts have said, with current triggers being June quarter earnings and more clarity on US tariffs on the sector. Analysts have suggested deploying a "buy on dips" strategy next week. The Nifty Pharma index is likely to find support at 21700 points and the resistance level is expected to be around 22230 points.
Brokerages expect pharmaceutical companies to post moderate growth in their Apr-Jun earnings. Prabhudas Lilladher expects pharmaceutical companies' earnings before interest, taxes, depreciation, and amortisation for the June quarter to grow moderately on the back of a high base effect. The US market revenue of the pharmaceutical companies could face pressure due to price erosion of the prescription drug gRevlimid, Nuvama Institutional Equities said in a research report.
According to Nirmal Bang Institutional Equities, the large-cap pharmaceutical companies such as Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Mankind Pharma, and Ajanta Pharma are expected to post more than 10% on-year growth in their revenue for the June quarter. The growth is likely to be driven by robust growth in the US on the back of key products including Revlimid and favourable currency movement.
The Nifty Pharma index ended nearly 1% higher Friday. Glenmark Pharmaceuticals was the biggest gainer in the index and rose over 14%. The stock rose Friday after it said late Thursday that it signed a deal with New York-based AbbVei for an oncology drug. The deal is being seen as one of the largest in the domestic pharma sector by analysts. Natco Pharma slipped nearly 4% and was the biggest loser in the Nifty Pharma index.
US President Donald Trump this week reiterated his warning of imposing a whopping 200% tariffs on pharmaceutical imports, and as such remains a key monitorable. A government source told Informist on Thursday that the Indian team is soon going to visit the US for further talks on a trade deal.
TOP HEADLINES
* Glenmark Pharma's arm, US co sign licensing agreement for cancer drug
* US FDA concludes inspection at Emcure Pharma's mfg unit with no observation
* Granules India extends 25.50-mln Swiss franc corporate guarantee for arm
* On Alkem Lab suit, HC says Allchem did not undertake to not enter B2C model
* IPO Alert: Anthem Biosciences sets price band at INR 540-570 per share
* Lupin in pact with Zentiva to commercialise biosimilar Certolizumab Pegol
* IPO Alert: Veeda Clinical gets SEBI approval for fresh issue, OFS
* ANALYSIS: Pharmaceutical cos post mixed performance in Jan-Mar of FY25
* HC upholds order to bar Rajasthan Aushdhalaya from using name akin to Liv.52
* Alembic Pharma CFO relinquishes post as part of leadership succession plan
* Death toll climbs to 42 at Sigachi Ind's Hyderabad plant; 8 still missing
* Biocon arm Biocon Biologics gets UK regulator nod for Denosumab biosimilars
* Piramal Pharma receives $2.4 mln in Astral SteriTech insolvency case
* Lupin launches Ipratropium Bromide nasal solution in US market
Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:
| Company | Price | Week-on-Week Change in % | Resistance | Support |
| Abbott India | 34420.00 | (-)0.90 | 34913.30 | 34063.30 |
| Alkem Laboratories | 4806.70 | (-)1.60 | 4909.60 | 4680.20 |
| Aurobindo Pharma | 1124.80 | (-)5.60 | 1150.10 | 1102.50 |
| Biocon | 374.20 | (-)1.50 | 379.80 | 369.40 |
| Cipla | 1485.00 | (-)1.90 | 1502.30 | 1461.30 |
| Divi's Laboratories | 6835.00 | (-)1.00 | 6935.70 | 6774.70 |
| Dr Reddy's Laboratories | 1254.70 | (-)4.00 | 1280.00 | 1238.60 |
| Gland Pharma | 1859.00 | (-)0.70 | 1902.80 | 1818.20 |
| GlaxoSmithKline Pharmaceuticals | 3243.80 | (-)1.20 | 3294.30 | 3200.10 |
| Glenmark Pharmaceuticals | 2181.10 | 19.20 | 2377.20 | 1996.40 |
| Granules India | 469.00 | (-)4.80 | 483.70 | 459.00 |
| Ipca Laboratories | 1449.60 | 1.90 | 1490.70 | 1410.90 |
| Laurus Labs | 790.20 | 1.80 | 801.90 | 781.50 |
| Lupin | 1894.70 | (-)4.40 | 1920.00 | 1862.40 |
| Natco Pharma | 961.80 | (-)3.70 | 1009.90 | 936.00 |
| Pfizer | 5517.00 | (-)4.60 | 5653.30 | 5358.30 |
| Sanofi India | 5911.00 | (-)2.80 | 6049.30 | 5807.30 |
| Sun Pharmaceutical Industries | 1672.00 | (-)0.30 | 1689.10 | 1653.70 |
| Torrent Pharmaceuticals | 3314.20 | (-)1.60 | 3389.00 | 3272.00 |
| Zydus Lifesciences | 979.60 | (-)2.10 | 993.40 | 963.10 |
| Nifty Pharma | 22225.90 | (-)0.70 | 22454.50 | 22010.60 |
| Nifty 50 | 25149.85 | (-)1.20 | 25393.90 | 25007.00 |
| S&P Bse Sensex | 82500.47 | (-)1.10 | 83259.60 | 82062.70 |
End
Reported by P. Madhu Kumar
Edited by Deepshikha Bhardwaj
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2025. All rights reserved.
To read more please subscribe
Share this Story:
